However, the clinical outcomes of PD‐1, LAG‐3, and CTLA‐4 targeting in MM are disappointing.[4] This lack of efficacy emphasizes the unique challenges of MM's immunosuppressive TME and the urgent need to identify novel therapeutic targets.[11] BM CD8+ TRM have garnered attention in MM. Here, CD8A is linked to Miyoshi myopathy.